Pictet Asset Management (Switzerland)’s Madrigal Pharmaceuticals MDGL Stock Holding History

Pictet Asset Management (Switzerland)’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$39.6M	Sell	171,330 -7,485	-4%	-$2.03M	0.05%	331
2023 Q1	$43.3M	Buy	178,815 +19,661	+12%	+$5.36M	0.05%	311
2022 Q4	$46.2M	Buy	159,154 +86,153	+118%	+$8.43M	0.07%	286
2022 Q3	$4.74M	Buy	73,001 +23,403	+47%	+$1.63M	0.01%	743
2022 Q2	$3.55M	Buy	+49,598	New	+$3.65M	﹤0.01%	836

Other funds holding MDGL

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Pictet Asset Management (Switzerland)'s MDGL Position: Q2 2023 in Review

Pictet Asset Management (Switzerland) reduced its Madrigal Pharmaceuticals (MDGL) stake by 4.2% in Q2 2023, selling an estimated $2.03M and leaving 171,330 shares worth $39.6M. The position accounts for 0.05% of the portfolio, ranked #331.

Pictet Asset Management (Switzerland) first reported a position in MDGL in Q2 2022 and has held it in 5 quarters since. The position peaked at $46.2M in Q4 2022. 208 funds tracked by Wall St. Rank hold MDGL as of Q2 2023.

Pictet Asset Management (Switzerland) held 171,330 shares of Madrigal Pharmaceuticals worth $39.6M as of Q2 2023.
Pictet Asset Management (Switzerland) sold 7,485 Madrigal Pharmaceuticals shares in Q2 2023, an estimated $2.03M.
Madrigal Pharmaceuticals made up 0.05% of Pictet Asset Management (Switzerland)'s portfolio in Q2 2023, its #331 holding.
Pictet Asset Management (Switzerland) first reported a position in Madrigal Pharmaceuticals in Q2 2022 and has held it in 5 quarters since.
Pictet Asset Management (Switzerland)'s Madrigal Pharmaceuticals position peaked at $46.2M in Q4 2022.
208 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2023.

Based on Pictet Asset Management (Switzerland)'s 13F filing for Q2 2023, filed 10 Aug 2023.